Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • GSK flags up pipeline as HIV drugs help it beat profit forecasts

    GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.

    30 July 2015 | Reuters
  • Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge

    Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted second-quarter profit that topped analysts’ estimates as revenue surged. Gilead raised its sales forecast for the year.

    30 July 2015 | Bloomberg
  • Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

    In a bid to push back against payers, Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient insurance coverage or the financial wherewithal to get the medicines otherwise.

    20 July 2015 | Wall Street Journal Pharmalot blog
  • TAG Pipeline Report

    2015 report on the pipeline for new HIV, HCV and TB drugs.

    17 July 2015 | TAG
  • Bold goal of stopping HIV is motivating great science

    The massive challenge of finding an HIV vaccine has unleashed stunning creativity in laboratories all over the world. While we work toward the long-term goal of a vaccine, we are also pulling in partners from many sectors to improve prevention, treatment, and access to options in the short term.

    13 July 2015 | Devex
  • Success at Glaxo's HIV Unit May Mean Having to Call It Quits

    HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose.

    10 July 2015 | Bloomberg
  • Bristol-Myers to stop new antiviral drug research

    Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said it will also discontinue its Hepatitis B and HIV early programs.

    26 June 2015 | Reuters
  • China rejects Gilead hepatitis C drug patent: advocacy group

    China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.

    19 June 2015 | Reuters
  • Don’t Weaken the F.D.A.’s Drug Approval Process

    The 21st Century Cures Act could substantially lower the standards for approval of many medical products, potentially placing patients at unnecessary risk of injury or death. While the legislation does not mandate this approach, it opens the door to it.

    12 June 2015 | New York Times
  • Trans-Pacific Partnership Transparency for the Big Pharma Wrecking Crew

    A new WikiLeak release of the recent draft text of the US-led proposal for the Trans-Pacific Partnership annex on Pharmaceuticals and Medical Devices shows how the fig-leaf of “transparency” and “procedural fairness” is being used to allow transnational pharmaceutical companies to subvert countries’ ability to make decisions about which drugs and medical devices they can afford to cover, in order to expand access for monopoly-priced medicines.

    12 June 2015 | Health Gap
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.